Ribociclib adjuvant + AI (HR+/HER2- early breast cancer; NATALEE)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-RIBOCICLIB DRUG-LETROZOLE |
|---|
| ID | REG-RIBOCICLIB-AI-ADJUVANT |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NATALEE-SLAMON-2024 SRC-NCCN-BREAST-2025 |
Notes
STUB — pending Co-Lead sign-off. NATALEE: 3-year adjuvant CDK4/6i for HR+/HER2- early breast cancer (stage II-III + selected stage I high-risk). Ribociclib adjuvant dose is 400 mg (NOT the 600 mg metastatic dose). Key distinction from abemaciclib (monarchE): ribociclib has BROADER eligibility (includes node-negative with risk features); however requires mandatory ECG/QTc monitoring at baseline and on-treatment (QT prolongation boxed warning — fatal arrhythmia risk). Concurrent AI required throughout 3 years of ribociclib, then AI continues to 5 years total. Strong CYP3A4 inhibitors increase ribociclib exposure — avoid or dose-reduce. Separate metastatic regimen: REG-AI-RIBOCICLIB (600 mg continuous dose).
Used By
Indication
IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB- IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB